Which of the existing diet pills works best?

Article from NEJM Journal Watch (NEJM Journal Watch) Injected Semaglutide Bested Other Weight-Loss Medications Semaglutide Injection Outperforms Other Weight-Loss Drugs for Weight Loss Review By Bruce Soloway, MD In a meta-analysis, Semaglutide The tolerability of glutide is similar to that of other weight loss drugs
.

The FDA currently approves five drugs (orlistat, naltrexone-bupropion, phentermine-topiramate, and glucagon-like peptide-1) to treat obese or overweight patients [ GLP-1] receptor agonists liraglutide and semaglutide injection)
.

To assess the relative efficacy and safety of these and other candidate weight loss drugs, the researchers conducted a network meta-analysis of 143 randomized trials of weight loss that compared any of the above drugs with placebo, no treatment, or other active drugs
.

The trials included 50,000 patients (unlimited for relevant comorbidities); all received concurrent life>
.

Phentermine-topiramate was the most effective in reducing weight compared with life>
.

The risk of adverse reactions leading to discontinuation was highest with naltrexone-bupropion compared with life>
.

However, in a post hoc analysis, semaglutide injection was significantly more effective than all other drugs (MD, -11.
4%) and had a similar risk of adverse events
.

Commentary Of the drugs currently approved for the treatment of overweight and obese adults, semaglutide injection appears to be the most effective, with adverse effects similar to other drugs approved for this indication
.

The safety and efficacy of oral semaglutide for weight loss are currently being studied
.

Reviewed article Shi Q et al.
Pharmacotherapy for adults with overweight and obesity: A systematic review and network meta-analysis of randomised controlled trials.
Lancet 2021 Dec 8; [e-pub].
(https://doi.
org/10.
1016 /S0140-6736(21)01640-8) Related Reading 1NEJM Journal Watch NEJM Journal Watch (NEJM Journal Watch) is published by the NEJM Group.
It invites internationally renowned doctors to comment on important papers in the medical field and helps doctors understand and apply the latest developments
.

"NEJM Frontiers of Medicine" translates several articles every week, publishes them on the app and official website, and selects 2-3 articles and publishes them on WeChat
.

Copyright Information This article was translated, written or commissioned by the NEJM Frontiers in Medicine, jointly created by Jiahui Medical Research and Education Group (J-Med) and The New England Journal of Medicine (NEJM)
.

The full text of the Chinese translation and the included figures are exclusively authorized by the NEJM Group
.

If you want to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.

Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal responsibility
.